Consensus IntelGenx Technologies Corp.

Equities

IGXT

US45822R1014

Delayed OTC Markets Other stock markets 02:41:53 2024-05-08 pm EDT			5-day change	1st Jan Change
0.1676 ^USD	-11.80%		-6.89%	+21.36%

Apr. 08	Intelgenx Announces First Parkinson?S Disease Patients Dosed with Montelukast Versafilm® in Phase 2 ?Montpark? Clinical Trial	CI
Apr. 05	IntelGenx Updates Status of Buprenorphine Buccal Film ANDA	MT

Evolution of the average Target Price on IntelGenx Technologies Corp.

Price target over the last 5 years

History of analyst recommendation changes

a53879caa95fd4f024.8R8b5Z6oeaIcOGYLnl-hGDuVvUNO1kgKAQZ_IKHOGUI.oXVjovXsDMdfYVZc_XLISErckAchnRt9U2IuZtH3KBGbQEGrqoVU8VBJLw~7bf0232fde66b3cd013547a96aedd6c7

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.19

Average target price